Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Addenbrooke's Hospital, Cambridge, United Kingdom Clinical Trials

A listing of Addenbrooke's Hospital, Cambridge, United Kingdom clinical trials actively recruiting patients volunteers.

RESULTS

Found (9) clinical trials

Clinical Trial to Evaluate the Safety and Effectiveness of GDC-0032 When Given Alongside Tamoxifen

To determine the recommended phase II dose (RPTD) of GDC-0032 in combination with tamoxifen in hormone receptor positive, HER2 negative metastatic breast cancer patients who have progressed after prior endocrine treatment .Description of toxicity profile, severity and frequency of adverse events (observed with the combination of GDC-0032 and tamoxifen To ...

Phase

0.03 miles

Learn More »

Systemic Therapy and Chemoradiation in Advanced Localised Pancreatic Cancer - 2

This study will evaluate the role of increasing radiotherapy dose and addition of nelfinavir to chemoradiotherapy (CRT) in patients with inoperable pancreatic cancer that has not spread beyond the pancreas. Currently in the United Kingdom (UK), either chemotherapy alone or chemotherapy followed by CRT can be used in the management ...

Phase

0.03 miles

Learn More »

Low Dose Interleukin-2 in Patients With Stable Ischaemic Heart Disease and Acute Coronary Syndromes

This Phase I/II trial will carefully examine the safety of low-dose IL-2 in cardiovascular patients where it is currently contraindicated. The planned doses will be given to the trial patients once a day, over five days as subcutaneous injections [ i) Part A : Repeated doses will be given in ...

Phase

0.03 miles

Learn More »

A Study to Evaluate Safety Efficacy Pharmacokinetics and Pharmacodynamics of Erdafitinib Plus JNJ-63723283 an Anti-PD-1 Monoclonal Antibody in Participants With Metastatic or Surgically Unresectable Urothelial Cancer With Selected FGFR Gene Alterations

This open-label (all people know identity of intervention) and multicenter (when more than one hospital or medical school team work on a medical research study) study of erdafitinib plus JNJ-63723283 in participants with advanced urothelial cancer with selected fibroblast growth factor receptor (FGFR) gene alterations who have progressed on or ...

Phase

0.03 miles

Learn More »

A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.

This is a phase I/II open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK) and antitumor activity of MEDI4736 in combination with olaparib in patients with advanced solid tumors, selected based on a rationale for response to olaparib. Patients will be poly (adenosine diphosphate-ribose) polymerase (PARP)-inhibitor and immunotherapy (IMT)-nave ...

Phase

0.03 miles

Learn More »

Study of OXB-102 (AXO-Lenti-PD) in Patients With Bilateral Idiopathic Parkinson's Disease

This study consists of two parts. Part A is an open-label dose-escalation phase in which patients are enrolled in cohorts and will receive one of approximately three escalating doses of OXB-102 (AXO-Lenti-PD). Part B is a randomized, double-blind phase in which patients will be randomized to either an active group ...

Phase

0.14 miles

Learn More »

Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents

This is a modular, phase I, 2 part, open-label, multicentre study of AZD6738, administered orally, in combination with cytotoxic chemotherapy regimens and/or novel anti-cancer agents, to patients with advanced/metastatic solid malignancies. The study design allows an escalation of the dose of AZD6738 in combination with the standard dose and schedule ...

Phase

0.27 miles

Learn More »

Oral Liquid 13-cis-retinoic Acid (13-CRA)

All patients requiring at least two cycles of 13-CRA therapy will be eligible for recruitment into the trial. 13-CRA will be prescribed to patients according to local treatment protocols at each clinical site. The dose administered will be 200mg/m2/day for both test and reference product. Patients with a body weight ...

Phase

2.25 miles

Learn More »

Cambridge Brain Mets Trial 1

Brain metastases occur in 20-40% of all patients with cancer, with an incidence 10 times higher than that of primary malignant brain tumours. patients with brain metastases are an underserved population. Overall they have a poor prognosis with a median survival of 1-2 months with corticosteroids and only 5-7 months ...

Phase

2.3 miles

Learn More »